** Shares of diagnostic test maker Exagen XGN.O down 16.8% post-market to $5.68 on equity offering news
** Vista, California-based co commences stock offering with Canaccord Genuity as sole bookrunner; deal size not disclosed
** It intends to use net proceeds for working capital, general purposes, and potentially acquire, in-license or invest in complementary technologies or business, per the SEC prospectus filing
** Co, which makes testing products that help in diagnosing auto-immune diseases such as rheumatism, has ~18 mln shares outstanding for ~$123 mln market cap
** Stock on Weds closed up 6.4% at $6.83, extending YTD gain to ~67%
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.